BiDRA: Bayesian Inference as a Robust Alternative to Non-Linear Regres-sion for Dose-Response Efficiency Metrics Assessment

Clicks: 24
ID: 326250
2026
Free PDF
Article Quality & Performance Metrics
Overall Quality
Not rated
Combines reader engagement with the AI quality analysis. This article has not been analysed, so there is no overall score — reader engagement is measured and shown alongside.
AI Quality Assessment
Not analyzed
Readership in this journal
Steady

Ranked #45 of 172 articles by views in Bioinformatics advances

Most read Least read

Bar heights use a square-root scale. Only the 120 most-read articles are drawn; the journal has 172 in total.

Mint this article as an NFT
Not yet minted

Create a permanent, verifiable on-chain record of this article on the Scimatic Network. The NFT is held in your Journament account, and you can withdraw it to your own wallet at any time.

5 SUSD one-off · no wallet required
Sign in to mint
Abstract
Abstract Motivation Dose-response metrics such as the half-maximal inhibitory concentration, high-dose response, and slope are central to drug discovery, yet standard Levenberg-Marquardt fits often produce biased or unsupported values for incomplete curves and lack uncertainty measures. In practice, this forces experimenters to visually inspect each curve fit to judge its reliability, a tedious, subjective, and non-scalable process. Results Across 421,405 public dose-response experiments from three large pharmacogenomic datasets, shared-concentration viability responses were highly consistent across biological replicates, making it reasonable to expect derived efficiency metrics to show comparable replicate behavior when supported by the data. However, Levenberg-Marquardt fits to incomplete curves often produced unsupported metric values, including inflated rates of observable potency estimates (>70% versus ∼39% complete curves), which could falsely suggest metric-level disagreement between similar replicate responses. BiDRA represents efficacy, potency, and slope as posterior distributions, allowing uncertainty to remain large when the data do not support precise metric inference. This avoids treating uncertainty-dominated responses as conflicting point estimates, exposes unsupported Levenberg-Marquardt estimates, and supports uncertainty-aware compound ranking. We illustrate its utility in a structure–activity relationship screen, demonstrating how posteriors enable robust, criteria-based selection in drug discovery settings. Availability and implementation BiDRA is implemented in Julia and available at https://github.com/lemieux-lab/bidra_robustness.
Reference Key
openalex_W7204004432 Use this key to autocite in the manuscript while using SciMatic Manuscript Manager or Thesis Manager
Authors Caroline Labelle, Petr Smirnov, Maud David, Mario Callejo, Benjamin Haibe-Kains, Anne Marinier, Sébastien Lemieux
Are you one of these authors? Claim your profile
Journal Bioinformatics advances
Year 2026
DOI
10.1093/bioadv/vbag245
URL
https://doi.org/10.1093/bioadv/vbag245
Keywords Keywords not found

Citations

No citations found. To add a citation, contact the admin at info@scimatic.org

Comments

No comments yet. Be the first to comment on this article.